Spinal Muscular Atrophy News and Research

RSS
Spinal muscular atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Over time, patients afflicted by SMA continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA.
iPierian raises $28 million from Series B equity financing closure

iPierian raises $28 million from Series B equity financing closure

Research on motor neuron subtype may provide useful therapy for neuron diseases

Research on motor neuron subtype may provide useful therapy for neuron diseases

Study finds genetic change in chromosome 4 causes FSHD

Study finds genetic change in chromosome 4 causes FSHD

Muscular Dystrophy Association awards $14.1M in new grants

Muscular Dystrophy Association awards $14.1M in new grants

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Dr. Hastings receives grant for Spinal Muscular Atrophy research

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Spinal muscular atrophy may lead to cardiac dysfunction: Study

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Long-term exposure to valproate leads to bone loss: Study

Long-term exposure to valproate leads to bone loss: Study

Braun Corporation presents key themes, recommendations discussed at symposium for the disabled

Braun Corporation presents key themes, recommendations discussed at symposium for the disabled

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

Today's OpEds: Health reform and long-term care; Health care incentives; Reasons for optimism or repeal and replace?

CSHL scientists reverse symptoms of Type III SMA using ASOs

CSHL scientists reverse symptoms of Type III SMA using ASOs

iPierian announces closing of $22M Series B equity financing round

iPierian announces closing of $22M Series B equity financing round

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

Researchers make significant headway in fight against SMA

Researchers make significant headway in fight against SMA

Novel gene replacement therapy holds promise for Spinal Muscular Atrophy

Novel gene replacement therapy holds promise for Spinal Muscular Atrophy

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Ohio scientists demonstrate existence of effective technology for nationwide newborn screening of SMA

Ohio scientists demonstrate existence of effective technology for nationwide newborn screening of SMA

CML, FightSMA Canada collaborate to find a cure for spinal muscular atrophy

CML, FightSMA Canada collaborate to find a cure for spinal muscular atrophy

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming

iPierian receives $1.5M Basic Biology Award from CIRM to study cellular reprogramming